Loading...
Price History
Market Data
| Market Cap | 13.16M |
| P/E Ratio | - |
| P/B Ratio | 0.57 |
| EPS | - |
| Dividend Yield | - |
| D/E Ratio | 2.04 |
| Current Ratio | 1.25 |
| Currency | USD |
Key Financial Metrics
195.17M
Revenue
15.47M
Net Income
-
EPS (Diluted)
20.15M
Free Cash Flow
Profitability
Gross Margin
85.8%
Operating Margin
-3.4%
Net Profit Margin
7.9%
EBITDA
-6.56M
Returns & Efficiency
Return on Assets (ROA)
22.0%
Return on Equity (ROE)
66.8%
Dividend Yield
-
EPS
-
Financial Health
Total Assets
70.41M
Total Debt
-
Debt to Equity
2.04x
Current Ratio
1.25
Insider Trading
Last 12 months
0
Buys
0
Sells
0
Insiders
Quick Access Filings
10-K
Annual Report
Loading...
10-Q
Quarterly Report
Loading...
8-K
Recent News
Loading...
Company Data Library
Earnings Transcripts
Loading...
Press Releases
Loading...
Filing Sections
Loading...
Company Info
| Industry | Chemicals & Allied Products |
| HQ | NEW YORK, NY |
| Fiscal Year | 2025 |
Peers
6.07B
P/E: 55.9
6.07B
P/E: 55.9
TELADOC, INC.
TDOC
1.22B
P/E: --
TELADOC HEALTH, INC.
TDOC
1.22B
P/E: --
247.97M
P/E: --
247.97M
P/E: --
28.80M
P/E: --
28.80M
P/E: --
Quick Links
Financial Statistics
Valuation
Market Cap$13.16M
P/E Ratio (TTM)-
Price to Book0.57
EV/Revenue-
EV/EBITDA-
Profitability
Gross Margin85.8%
Operating Margin-3.4%
Net Margin7.9%
ROE66.8%
ROA22.0%
Leverage & Liquidity
Debt to Equity2.04
Current Ratio1.25
Total Debt-
Total Assets$70.41M
Stockholders' Equity$23.16M
Income Statement (FY 2025)
Revenue$195.17M
Gross Profit$167.45M
Operating Income$-6.56M
Net Income$15.47M
EPS (Diluted)-
Cash Flow (FY 2025)
Free Cash Flow$20.15M
Cash & Equivalents$36.79M
Revenue Growth0.6%
SEC Filings by Category
Insider Trading Activity
Neutral
0 Buys $0
0 Sales $0
0 Exercises $0
Net: $0
| Insider | Title | Date | Type | Shares | Price | Value |
|---|
Company Information
| Business Address | 236 FIFTH AVENUE SUITE 400 NEW YORK, NY 10001 |
| Phone | N/A |
| Incorporated | DE, US |
| EIN | 760238453 |
| Fiscal Year End | 1231 |
| Shares Outstanding | 554,064.00 |
| Stockholders' Equity | $23.16M |
| Cash & Equivalents | $36.79M |
Recent Filings
View All
ARS
Annual Report to Shareholders
Annual report furnished to shareholders
Filed: 2026-04-30
Local
DEFA14A
Additional Proxy Materials
Additional definitive proxy soliciting materials
Filed: 2026-04-30
Local
DEFA14A
Additional Proxy Materials
Additional definitive proxy soliciting materials
Filed: 2026-04-30
Local
DEF 14A
Definitive Proxy Statement
Official proxy statement for shareholder voting
Filed: 2026-04-30
Local
4
Insider Transaction Report
Statement of changes in beneficial ownership
Filed: 2026-04-01
Local
3
Initial Ownership Report
Initial statement of beneficial ownership of securities
Filed: 2026-04-01
Local
3
Initial Ownership Report
Initial statement of beneficial ownership of securities
Filed: 2026-04-01
Local
S-8
Employee Plan Registration
Registration for employee benefit plan securities
Filed: 2026-04-01
Local
8-K
Current Report
Report of material events (acquisitions, earnings, executive changes)
Filed: 2026-03-18
Local
10-K
Annual Report
Comprehensive annual financial report with audited statements
Filed: 2026-03-10
Local
8-K
Current Report
Report of material events (acquisitions, earnings, executive changes)
Filed: 2026-03-09
Local
10-Q
Quarterly Report
Quarterly financial report with unaudited statements
Filed: 2025-11-17
Local
10-Q
Quarterly Report
Quarterly financial report with unaudited statements
Filed: 2025-08-05
Local
10-Q
Quarterly Report
Quarterly financial report with unaudited statements
Filed: 2025-05-06
Local
DEF 14A
Definitive Proxy Statement
Official proxy statement for shareholder voting
Filed: 2025-04-28
Local
Loading...
Loading management data...
Loading...
Loading board of directors...
Loading...
Loading institutional holders...
Loading...
Loading short interest data...
Financial Charts Annual (10-K)
Interactive financial visualizations
Show:
Revenue & Income Trends
Revenue & Profit
Profit Margins
Balance Sheet Breakdown
Assets Composition
Capital Structure
Cash Flow Analysis
Cash Flow Components
Free Cash Flow
Growth & Performance
Revenue Growth Rate (YoY %)
Key Ratio Trends
Company Profile
General Information
| Company Name | LifeMD, Inc. |
| Ticker | LFMDP |
| Exchange | -- |
| Sector | Manufacturing |
| Industry | Chemicals & Allied Products |
| Headquarters | NEW YORK, NY |
| Fiscal Year | 2025 |
Financial Summary
| Market Cap | 13.16M |
| Revenue | 195.17M |
| Net Income | 15.47M |
| P/E Ratio | - |
| EPS | - |
| Net Margin | 7.9% |
| ROE | 66.8% |
| Dividend Yield | - |
Insider Transactions
Loading...
My Notes & Files
Personal Notes
Attached Files
Loading...